Sugi Predict

Sugi Predict / Compounds / SCHEMBL1615595

SCHEMBL1615595

SCHEMBL1615595

CC1(C)CCC(C)(C)c2cc(/C=C\c3ccc(C(=O)O)cc3)ccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RARB P10826 13/20 1.00
▸ RARG P13631 13/20 1.00
▸ RARA P10276 10/20 1.00
▸ RXRA P19793 12/20 0.72
▸ CYP26A1 O43174 3/20 0.68
▸ CYP3A4 P08684 2/20 0.68
▸ KDM4E B2RXH2 1/20 0.68
▸ NPC1 O15118 1/20 0.68
▸ GMNN O75496 1/20 0.68
▸ USP2 O75604 1/20 0.68
▸ ALDH1A1 P00352 1/20 0.68
▸ LMNA P02545 1/20 0.68
▸ TP53 P04637 1/20 0.68
▸ CYP1A2 P05177 1/20 0.68
▸ POLB P06746 1/20 0.68
▸ CYP2D6 P10635 1/20 0.68
▸ NFKB1 P19838 1/20 0.68
▸ CYP2C19 P33261 1/20 0.68
▸ THPO P40225 1/20 0.68
▸ MTOR P42345 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616018 1.00 RARB (1.00) RARBRARGRARARXRACYP26A1
SCHEMBL1615597 1.00 RARB (1.00) RARBRARGRARARXRACYP26A1
SCHEMBL9747847 0.89 RARB (0.80) RARBRARGRARARXRACYP26A1
4-Aminophenol SCHEMBL10842256 0.89 RARB (0.79) RARBRARGRARARXRACYP26A1
4-Aminophenol SCHEMBL10842270 0.89 RARB (0.79) RARBRARGRARARXRACYP26A1
SCHEMBL8026153 0.88 RARB (0.78) RARBRARGRARARXRACYP26A1
SCHEMBL4315172 0.86 RARB (0.75) RARBRARGRARARXRACYP26A1
SCHEMBL4315169 0.86 RARB (0.75) RARBRARGRARARXRACYP26A1
SCHEMBL1615307 0.85 RARB (0.74) RARBRARGRARARXRACYP26A1
SCHEMBL1615305 0.85 RARB (0.74) RARBRARGRARARXRACYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120039609-A Semi-automatic glutinous rice chicken production line 广东华饮食品供应链管理有限公司 2025-05-27 — — CN disclosed
CN-119823924-A Recombinant microorganism for producing alpha-ketoisovalerate, and preparation method and application thereof 中国科学院天津工业生物技术研究所 2025-04-15 — — CN disclosed
CN-118562989-B Method for screening streptococcus salivarius thermophilus subspecies producing aroma based on diacetyl reductase 北京和益源生物技术有限公司 2024-10-01 — — CN disclosed
CN-118726215-A Recombinant microorganism for producing pantoic acid and application thereof 安徽华恒生物科技股份有限公司 2024-10-01 — — CN disclosed
CN-118562989-A Method for screening streptococcus salivarius thermophilus subspecies with high yield based on diacetyl reductase 北京和益源生物技术有限公司 2024-08-30 — — CN disclosed
US-20240148036-A1 GLUCOSYL STEVIA COMPOSITION PURECIRCLE SDN BHD (MY) 2024-05-09 — — US disclosed
US-11950610-B2 Glucosyl Rebaudioside C PURECIRCLE SDN BHD (MY) 2024-04-09 — — US disclosed
US-11871771-B2 Glucosyl Stevia composition PURECIRCLE SDN BHD (MY) 2024-01-16 — — US disclosed
US-20230270146-A1 GLUCOSYL STEVIA COMPOSITION PURECIRCLE SDN BHD (MY) 2023-08-31 — — US disclosed
CN-116434773-A Multi-note estimation method and device based on optimal parameter model 江苏理工学院 2023-07-14 — — CN disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 — — US disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 — — US disclosed
US-7923579-B2 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2011-04-12 — — US disclosed
EP-1692097-B1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2009-09-02 — — EP disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 — — US disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 — — US disclosed
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods EXONHIT THERAPEUTICS S.A. (FR) 2007-06-07 — — US disclosed
EP-1692097-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS Exonhit Therapeutics SA (FR) 2006-08-23 — — EP disclosed
WO-2005058803-A1 TRICYCLIC HYDROXAMATE AND BENZAMIDE DERIVATIVES, COMPOSITIONS AND METHODS EXONHIT THERAPEUTICS SA (FR) 2005-06-30 — — WO disclosed
EP-1541549-A1 Tricyclic hydroxamate and benzaminde derivatives, compositions and methods Exonhit Therapeutics S.A. (FR) 2005-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129368-A1 Tricyclic hydroxamate and benzamide derivatives, compositions and methods HDAC5, HDAC1, HDAC2 RARB 998/4885RARG 904/4885RARA 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.